These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15185321)

  • 41. The relationship between iron overload and clinical characteristics in a Spanish cohort of 100 C282Y homozygous hemochromatosis patients.
    Altes A; Ruiz A; Martinez C; Esteve A; Vela MD; Remacha AF; Sarda P; Bach V; Baiget M
    Ann Hematol; 2007 Nov; 86(11):831-5. PubMed ID: 17639389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al.
    Valenti L; Dongiovanni P; Fracanzani AL; Fargion S
    Diabetes Care; 2008 Mar; 31(3):e18; author reply e19. PubMed ID: 18308681
    [No Abstract]   [Full Text] [Related]  

  • 43. Risk of iron overload in carriers of genetic mutations associated with hereditary haemochromatosis: UK Food Standards Agency workshop.
    Singh M; Ashwell M; Sanderson P; Cade J; Moreton J; Fairweather-Tait S; Roe M; Marx JJ; Worwood M; Cook JD
    Br J Nutr; 2006 Oct; 96(4):770-3. PubMed ID: 17010238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic predisposition to iron overload: prevalence and phenotypic expression of hemochromatosis-associated HFE-C282Y gene mutation.
    Distante S
    Scand J Clin Lab Invest; 2006; 66(2):83-100. PubMed ID: 16537242
    [No Abstract]   [Full Text] [Related]  

  • 45. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases.
    Barton JC; Lee PL; West C; Bottomley SS
    Am J Hematol; 2006 Oct; 81(10):760-7. PubMed ID: 16838333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of the HFE gene (H63D and C282Y) mutations in patients with iron overload, family members and controls from Antioquia, Northwest Colombia.
    Avila-Gomez IC; Latorre-Sierra G; Restrepo-Gutierrez JC; Correa-Arango G; Jimenez-Del-Rio M; Velez-Pardo C
    Clin Genet; 2008 Jan; 73(1):92-3. PubMed ID: 18005180
    [No Abstract]   [Full Text] [Related]  

  • 47. [HFE gene mutations and risk of hepatocellular carcinoma].
    Solís Herruzo JA; Solís Muñoz P
    Rev Esp Enferm Dig; 2007 Jul; 99(7):369-75. PubMed ID: 17973579
    [No Abstract]   [Full Text] [Related]  

  • 48. The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations.
    Neri S; Pulvirenti D; Signorelli S; Ignaccolo L; Tsami A; Mauceri B; Misseri M; Interlandi D; Cutuli N; Castellino P
    Intern Med J; 2008 Apr; 38(4):254-8. PubMed ID: 17916170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation.
    Stuart KA; Fletcher LM; Clouston AD; Lynch SV; Purdie DM; Kerlin P; Crawford DH
    Hepatology; 2000 Dec; 32(6):1200-7. PubMed ID: 11093725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron genes, dysmetabolism and fibrosis in chronic hepatitis C.
    Valenti L; Dongiovanni P; Fargion S; Fracanzani AL
    J Hepatol; 2008 Mar; 48(3):513-4; author reply 514-5. PubMed ID: 18194822
    [No Abstract]   [Full Text] [Related]  

  • 51. The influence of hemochromatosis mutations on iron overload of thalassemia major.
    Longo F; Zecchina G; Sbaiz L; Fischer R; Piga A; Camaschella C
    Haematologica; 1999 Sep; 84(9):799-803. PubMed ID: 10477452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen?
    Ioannou GN; Kowdley KV
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):246-8. PubMed ID: 15017663
    [No Abstract]   [Full Text] [Related]  

  • 53. HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload.
    Remacha AF; Carrasco M; Sardá MP; Barceló MJ; Baiget M
    Haematologica; 1999 Mar; 84(3):284-5. PubMed ID: 10189401
    [No Abstract]   [Full Text] [Related]  

  • 54. Natural history of hemochromatosis.
    Beutler E
    Mayo Clin Proc; 2004 Mar; 79(3):305-6. PubMed ID: 15008601
    [No Abstract]   [Full Text] [Related]  

  • 55. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
    Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
    [No Abstract]   [Full Text] [Related]  

  • 56. [Iron as comorbid factor in chronic hepatitis C].
    Erhardt A; Hauck K; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):685-91. PubMed ID: 14685669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The S65C mutation in Spain. Implications for iron overload screening.
    Remacha AF; Barceló MJ; Sardà MP; Blesa I; Altés A; Baiget M
    Haematologica; 2000 Dec; 85(12):1324-5. PubMed ID: 11114141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Iron overload disease: recent findings].
    Licata A; Brucato V; Di Marco V; Barbaria F; Craxì A
    Ann Ital Med Int; 2004; 19(3):145-54. PubMed ID: 15529941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis.
    Nahon P; Ganne-Carrié N; Trinchet JC; Beaugrand M
    Gastroenterol Clin Biol; 2010 Jan; 34(1):1-7. PubMed ID: 19762191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Obscure pathogenesis of primary iron overload in Indians warrants more focused research.
    Das R; Chandak GR
    Indian J Gastroenterol; 2011 Jul; 30(4):154-5. PubMed ID: 21847604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.